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Abstract Background: Neoadjuvant anti-tumor activity of an alternating taxane- and
anthracycline-based dose-dense regimen in patients with operable, non-
inflammatory large breast cancer was investigated.
Objective: The objective is to study the rate of pathological complete re-
sponse in patients with breast cancer receiving dose-dense chemotherapy
sequentially with gemcitabine plus docetaxel and vinorelbine plus epirubicin.
Methods: Women (n = 74) with clinical stage II or III breast cancer were en-
rolled in this open-label, multicenter study to receive six 2-weekly courses of
gemcitabine 1000mg/m2 plus docetaxel 75mg/m2 on days 1 and 15, and
vinorelbine 25mg/m2 plus epirubicin 100mg/m2 on days 29 and 43. Patients
with an objective response on day 56 then received another cycle of gemci-
tabine/docetaxel on day 57 and of vinorelbine/epirubicin on day 71. Con-
servative surgery was scheduled for all patients.
Results: Of the patients enrolled, 30% had triple-negative breast cancer
(TNBC). The pathologic complete response (pCR) rate was 22% overall,
but was higher in TNBC than patients without TNBC (40.9% vs 14.0%;
p = 0.028). Among patients with a pCR, patients with TNBC had similar
recurrence-free survival (RFS) and overall survival (OS) to patients without
TNBC. Among those without a pCR, RFS rates for patients with TNBCwere
significantly lower than for patients without TNBC (p= 0.04). The most
common severe hematologic toxicity was neutropenia.
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Conclusions: Administering four drugs in a dose-dense alternating sequence
gave a high pCR in patients with operable, invasive breast cancer. Patients
with TNBC with a pCR had similar OS to patients without TNBC, whereas
patients with TNBC without a pCR had poorer survival rate than their non-
TNBC counterparts.
Introduction
Neoadjuvant chemotherapy reduces tumor
burden, thus allowing the possibility of breast-
conserving surgery.[1,2] It is believed to treat clin-
ically undetectable micrometastases[3] and allows
for monitoring of tumor response to therapy.[4]
Neoadjuvant therapy has recently become more
commonly used in patients with larger tumors
and/or lymph node involvement at diagnosis.
Although no single chemotherapy regimen is
specifically recommended over other regimens,
regimens tend to be anthracycline-based with the
addition of a taxane for high-risk, node-positive
disease.
There is a clear association between breast can-
cer subtype and patient outcomes. Patients with
‘triple-negative’ breast cancer (TNBC), where
tumors are estrogen receptor (ER)-, progesterone
receptor (PR)-, and human epidermal growth
factor receptor 2 (HER2)-negative tend to pres-
ent with large, high-grade tumors.[5-8] TNBC is
associated with aggressive clinical features,[9,10]
poor prognosis,[7,8,11] and a high rate of local re-
lapse.[12] There is some evidence that TNBC is
probably one of the more chemosensitive sub-
types,[13,14] but the most effective agents are cur-
rently unknown.[15] The genetic instability of
these TNBCs is expected to lead to an increased
potential for resistance to treatments, which may
eventually be reduced by the use of combination
and sequential regimens.[15] Dose-dense chemo-
therapy (2-weekly intervals between cycles) may
improve long-term outcomes relative to standard
3-weekly schedules.[16] Sequential chemotherapy
allows dose intensity to be maintained in order
to preserve efficacy and reduce toxicity,[16] and
the sequential administration of taxanes and an-
thracyclines has demonstrated high anti-tumor
activity in the neoadjuvant setting.[17]
A pathologic complete response (pCR) rate of
26% was achieved in a small phase I/II study of
docetaxel in combination with gemcitabine and
epirubicin given as intensive (six cycles) neoadju-
vant therapy in patients with early breast cancer,
suggesting that this combination is highly active.[18]
Therefore, the anti-tumor activity of gemcitabine
plus docetaxel and of vinorelbine plus epirubicin
given as neoadjuvant therapy to patients with
large, operable, invasive breast tumors was in-
vestigated. To achieve appropriate dose intensity
of each agent whilst limiting cumulative toxicity,
an alternating sequence of these two combination
regimens was designed, which were given every
2 weeks.
First, a pilot safety study of the regimen in
13 patients with breast cancer was conducted,
which demonstrated promising efficacy (own un-
published data). Given these encouraging results,
the current study was conducted.We propose this
regimen to be referred to as GTEN (Gemzar
Taxotere Epirubicin Navelbine).
Materials and Methods
This was an open-label, prospective, phase II
trial conducted in two centers in Paris, France.
All patients provided written informed consent
and the study was conducted with local Ethics
Committee approval and in accordance with
Good Clinical Practice and the Declaration of
Helsinki.
Patients
Women aged 18–75 years with chemotherapy-
naı¨ve, histologically-proven breast adenocarcinoma
with a clinically-determined tumor size of ‡3 cm
or local lymph node involvement, assessed clinically,
and adequate blood cell counts, liver function,
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renal function and cardiac function were enrolled.
Patients were excluded if they had inflammatory
breast cancer, known overexpression (an im-
munohistochemical [IHC] score of ‡2+) of HER2
or metastatic disease.
Study Protocol
Patients received between four and six 2-week
cycles of chemotherapy, starting with two cycles
of docetaxel 75mg/m2 plus gemcitabine 1000mg/m2
(cycle 1 on day 1 and cycle 2 on day 15) followed
by two cycles of vinorelbine 25mg/m2 plus epi-
rubicin 100mg/m2 (cycle 3 on day 29 and cycle 4
on day 43). Thereafter, patients without an ob-
jective response (determined clinically or radio-
logically), underwent surgery with axillary lymph
node dissection; those with an objective response
received one cycle of docetaxel plus gemcitabine
at the same dose (cycle 5 on day 57) followed by
one cycle of vinorelbine plus epirubicin at the
same dose (cycle 6 on day 71). For patients who
had received six cycles, at the final assessment on
day 85, patients without an objective response were
treated off-protocol whilst those with an objective
response underwent surgery with axillary lymph
node dissection. Thus, all patients in the study were
scheduled to undergo conservative surgery. Figure 1
summarizes the protocol description.
Treatment was delayed by 1 week for hema-
tologic toxicity, defined as an absolute neutrophil
count of <1.0 · 109/L and/or platelet count of
<100 · 109/L in the 24 hours prior to treatment.
All patients received filgrastim 5 mg/kg sub-
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Fig. 1. The timing of chemotherapy administration and evaluation of tumor response. D =day.
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Planned Interim Analyses
Treatment response was assessed at two in-
terim analyses (based on the Simon two-stage
minimax design[19]) as follows: if more than three
complete pathologic responses were observed in
the first 21 evaluable patients at the first analysis,
then a further 28 patients were enrolled. If the
cumulative total number of pathologic responses
was ‡11 at the second analysis of evaluable pa-
tients (of the 49 enrolled), the treatment was con-
sidered effective and enrollment could continue.
If at either analysis these criteria were not met,
the study would be discontinued.
Clinical Response Criteria
The pCR was determined by microscopic
examination of the excised tissues from the breast
and regional lymph nodes, and was defined as no
residual disease in either tissue. A lymph node
response was defined as an absence of axillary
lymph node involvement as determined by micro-
scopic examination of excised tissue after treatment
(pN-) in patients who had lymph node involve-
ment at baseline (N+). The objective response by
clinical or radiological criteria was determined
according to Response Evaluation Criteria in
Solid Tumors (RECIST 1.0).[20]
Efficacy Endpoints and Assessments
The primary efficacy endpoint was the propor-
tion of patients with a pCR. Secondary efficacy
endpoints included overall survival (OS) [defined
as the time from tumor diagnosis to death], re-
currence-free survival (RFS) [defined as patients
alive and without recurrent disease as from the
first day of tumor diagnosis to the time of first
local or metastatic recurrence or tumor-related
death], and the rate of metastatic and local recur-
rence. Exploratory analyses included the propor-
tion of patients with residual disease, an analysis
of lymph node response by baseline lymph node
involvement, and IHC analyses of tissue from the
initial biopsy for ER, PR, and HER2 status.[21]
ER (clone 6F11, diluted 1 : 30) and PR (clone
PGR-312, diluted 1 : 100) monoclonal antibodies
were purchased fromNovocastra (Newcastle upon
Tyne, UK), and HER2 (clone A0485, diluted
1 : 600) from Dako (Glostrup, Denmark). An ex-
ploratory analysis was also conducted for treat-
ment response and survival parameters in TNBC
and non-TNBC.
Clinical tumor evaluation, breast ultrasound,
and mammography were performed after the
fourth and sixth cycles of chemotherapy.
Safety and Laboratory Assessments
Patients had a complete laboratory and vital
sign (temperature, pulse, blood pressure) assess-
ment 1 week prior to study inclusion and also
during the study. Tests performed included a
weekly complete blood count, vital signs mea-
surement on treatment administration days, and
blood biochemistry before each cycle, and mea-
surement of cardiac parameters by ultrasound or
scintigraphy after two cycles and at the end of
every cycle thereafter. Adverse events and tox-
icities were assessed at every cycle according to
National Cancer Institute Common Toxicity Cri-
teria version 2.[22]
Statistical Methods
To achieve a statistical power of 80%, assum-
ing a minimum acceptable pCR rate of 15% and
that 85% of patients would be evaluable, enroll-
ment of 57 patients was required (in two stages,
see the ‘Planned Interim Analyses’ section). The
intent-to-treat (ITT) and safety populations in-
cluded patients who received at least one cycle of
study drug, and the per-protocol population in-
cluded those evaluable for response and who re-
ceived the scheduled study medication (at least
three cycles of study drug).
Categorical variables were compared using the
Chi-squared test or the Fisher exact test and con-
tinuous variables were compared using ANOVA
between TNBC and non-TNBC.
We compared Kaplan-Meier curves for OS
and RFS with the log-rank test for several vari-
ables (e.g. age, tumor size, positivity of lymph
node, clinical stage, histologic grade, positivity of
hormone receptors, TNBC subtypes, pCR). Un-
adjusted hazard ratios (HR) were calculated for
each studied variable. All p-values were two-sided.
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Analyses were undertaken with Stata 9.2 (Stata
corporation).
Results
Seventy-four patients were enrolled between
December 2002 and December 2006, and all were
included in the ITT and safety populations. One
patient received chemotherapy but refused surgery,
thus there were 73 patients in the per-protocol
population. Patient baseline demographic and
disease characteristics are given in table I. Most
patients had invasive ductal tumors (89%), tumor-
node-metastasis (TNM) clinical stage II (81%),
and Elston and Ellis histologic grade II (44%)
or III disease (23%). Contrary to enrollment cri-
teria, a small proportion of patients with HER2-
positive (HER2+) disease were enrolled (two
patients expressed ++HER2). Twenty-two patients
had TNBC and 51 had non-TNBC (data missing
Table I. Patient (pt) clinical characteristics
Characteristic Total TNBCa Non-TNBC p-Valueb
No. of pts enrolled 74 22 51
Age [n/N (%)]
<50 y 38/74 (51.4) 11/22 (50.0) 27/51 (52.9) 0.82
‡50 y 36/74 (48.6) 11/22 (50.0) 24/51 (47.1)
Mean tumor size [cm–SD]








pN+ on clinical examination [n/N (%)] 28/70 (40.0) 10/20 (50.0) 19/50 (65.5) 0.36
Clinical stagec [n/N (%)]
I 1/71 (1.4) 0/20 (0) 1/50 (2.0) 1.00
II 58/71 (81.7) 17/20 (85.0) 40/50 (80.0)
III 12/71 (16.9) 3/20 (15.0) 9/50 (18.0)
Histologic tumor type [n/N (%)]
invasive ductal 66/74 (89.2) 21/22 (95.4) 45/51 (88.2) 0.67
Other 8/74 (10.8) 1/22 (4.6) 6/51 (11.8)
Histologic graded [n/N (%)]
1 8/74 (10.8) 2/22 (9.0) 6/51 (11.7) 0.001
2 33/74 (44.6) 3/22 (13.6) 30/51 (58.8)
3 17/74 (23.0) 10/22 (45.4) 7/51 (13.7)
not specified 16/74 (21.6) 7/22 (32.6) 8/51 (15.7)
Estrogen receptor status [n/N (%)]
Positive 43/74 (58.1) 0/22 (0) 43/51 (84.3) <0.001
Negative 31/74 (41.9) 22/22 (100) 8/51 (26.7)
Progesterone receptor status [n/N (%)]
Positive 28/74 (37.8) 0/22 (0) 28/51 (54.9) <0.001
Negative 46/74 (62.2) 22/22 (100) 23/51 (45.1)
HER2 expression [n/N (%)]
2+/3+ 9/74 (12.2) 0/22 (0) 9/51 (17.6) 0.05
0/1+ 61/74 (82.4) 20/22 (90.9) 40/51 (78.4)
Unknown 4/74 (5.4) 2/22 (9.1) 2/51 (3.9)
a For one patient, data are missing for the TNBC/non-TNBC status.
b p-Value of test comparing distribution of TNBC/non-TNBC for the various characteristics.
c Clinical staging using American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system.
d Histologic grade using Elston and Ellis histologic classification.[23]
HER2 =human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.
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for one patient). Histologic grade was sig-
nificantly higher in TNBC than patients without
TNBC (p = 0.001).
Treatment
Three patients had at least three cycles of che-
motherapy. Five patients received the first four
cycles of chemotherapy but proceeded to surgery
thereafter because they did not have an objective
response at the first assessment. Sixty-five patients
received more than four cycles, of whom 35 un-
derwent mastectomy and 30 breast-conserving
surgery; all patients had lymph node dissection.
Eight patients discontinued chemotherapy because
of adverse events and therefore did not receive all
six chemotherapy cycles. At the final assessment
(day 85), only one patient was without an objective
response and was treated off-protocol by surgery.
Mean cumulative doses were docetaxel
215mg/m2 (95% of planned dose), gemcitabine
2878mg/m2 (95% of planned dose), vinorelbine
68mg/m2 (90% of planned dose), and epirubicin
275mg/m2 (91% of planned dose).
All patients (n = 32) who underwent tumor-
ectomy received radiotherapy, as well as those
who underwent mastectomy with T3 or greater
tumor size or with three or more lymph node
involvement. No further chemotherapy was pre-
scribed. All patients with positive ER and/or PR
received hormonal therapy. Twopatients withHER
over-expression received adjuvant trastuzumab.
Treatment Response
A pCR was observed in 21.9% of patients
(table II). Of the 28 of 70 patients who had pos-
itive lymph nodes on clinical examination, over
one-third of patients had a lymph node response.
Of note, pCR occurred in significantly more
TNBC than patients without TNBC (40.9% vs
14.0%; p= 0.028). The corresponding proportion
of patients with residual disease was therefore
significantly lower in the TNBC than non-TNBC
group (p = 0.028). More patients with a lymph
node response tended to have non-TNBC than
TNBC disease (44.4% vs 20.0%), although this
difference was not significant.
Most of the patients with no lymph node in-
volvement prior to neoadjuvant therapy remain-
ed node-negative at surgery (35 of 42 patients).
Seven patients with clinically lymph node negative
at baseline, had lymph node positive, diagnosed
pathologically, after surgery. Of the 28 patients
with node-positive disease prior to treatment, ten
had no evidence of disease at surgery (table III).
Moreover, the proportion of patients who experi-
enced a local recurrence was very low (1.4%), and
distant metastases were reported in 19% of patients
after neoadjuvant therapy (table II). The difference
between patients with TNBC and non-TNBC for
these two endpoints was not significant.
Survival Parameters
After a median follow-up of 3.18 years, OS and
RFS rates were 91.9% and 79.7%, respectively
Table II. Treatment response and patient outcomes [n/N (%)]
Variable Total TNBCa Non-TNBC
Primary endpoint
pCRb 16/73 (21.9) 9/22 (40.9)* 7/50 (14.0)
Exploratory endpoints
Residual disease 57/73 (78.1) 12/22 (54.6)* 43/50 (86.0)
Lymph node responsec 10/28 (35.7) 2/10 (20.0)** 8/18 (44.4)
Secondary endpoints
Local recurrence 1/74 (1.4) 0/22 (0) 1/51 (2.0)
Distant metastasis 14/74 (18.9) 6/22 (27.3) 7/51 (13.7)
Overall survival 68/74 (91.9) 19/22 (86.4) 48/51 (94.1)
Recurrence-free survival 59/74 (79.7) 16/22 (72.7) 43/51 (84.3)
a For one patient, data aremissing for the TNBC/non-TNBC status.
b One patient did not undergo surgery.
c Patients with node-positive disease (N1, N2, or N3) by clinical
examination at baseline who were classified pN0 by pathologic
examination after treatment and had a lymph node response.
pCR = pathologic complete response; TNBC = triple-negative breast
cancer; * p =0.028 vs non-TNBC (Fisher’s Exact test), ** p= 0.25 vs
non-TNBC (Fisher’s Exact test).
Table III. Lymph node response to treatment by baseline lymph
node status in evaluable patients (pts) [n =70]
Pathologic lymph node
(pN) status at surgery
Clinical lymph node status at baseline (n)
N- N+ total no. of pts
pN- 35 10 45
pN+ 7 18 25
Total no. of pts 42 28 70
N = lymph node.
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(table II). The 3- and 5-year estimates of OS were
95% and 81%, respectively, and of RFS were 84%
and 65%, respectively. Notably, there were no
statistically significant differences between
patients with TNBC or with non-TNBC in terms
of survival parameters (table II).
We conducted a univariate analysis to identify
prognostic factors for OS and RFS (table IV).
Baseline lymph node involvement or advanced
disease were prognostic of poorer RFS, and
baseline high clinical stage was prognostic of
poorer OS. However, pCR did not appear to be a
prognostic factor for either RFS or OS.
In patients with TNBC achieving a pCR, OS
was similar to that of patients without TNBC
with a pCR (5-year estimates of OS = 100% for
both). Among patients without a pCR, there was
a trend towards lower OS in patients with TNBC
than non-TNBC (3- and 5-year OS estimates
were 84% and 42% for TNBC, and 97% and 82%
for non-TNBC; p = 0.07) but the difference was
not significant. Similarly, among patients with a
pCR, the RFS of patients with TNBC was no
different from that in patients with non-TNBC
(3- and 5-year RFS estimates were 100% and 75%
for TNBC and, 100% and 67% for non-TNBC;
Table IV. Unadjusted analysis using the Cox’s model for overall survival (OS) and recurrence-free survival (RFS) of prognostic factors in
the intent-to-treat population (n =74)a
Variable OS RFS
critical events [n/N] HR (95% CI) p-value critical events [n/N] HR (95% CI) p-value
Age group
<50 y 4/38 1 p =0.39 9/38 1 p= 0.40
‡50 y 2/36 0.48 (0.09, 2.7) 6/36 0.64 (0.23, 1.8)
Baseline nodal status
N- 2/42 1 p =0.15 3/42 1 p= 0.001
N+ 4/29 3.25 (0.59, 17.9) 11/29 6.5 (1.8, 23.3)
Baseline clinical stage
I 0/1 – 0/1 –
II 2/58 1 p = 0.004 8/58 1 p = 0.005
III 4/12 3.2 (1.4, 7.6) 6/12 4.9 (1.7, 14.3)
Baseline histologic Elston and Ellis grade[24]
1 1/8 1 p =0.33 1/8 1 p= 0.38
2 2/33 0.32 (0.03, 3.8) 5/33 0.92 (0.11, 8.1)
3 3/17 1.1 (0.11, 11.3) 5/17 2.11 (0.24, 18.5)
Estrogen receptor status
Negative 3/31 1 p =0.75 8/31 1 p= 0.35
Positive 3/43 0.77 (0.15, 3.9) 7/43 0.62 (0.22, 1.7)
Progesterone receptor status
Negative 5/46 1 p =0.23 11/46 1 p= 0.27
Positive 1/28 0.27 (0.03, 2.4) 4/28 0.53 (0.17, 1.7)
Pathologic response
Complete response 0/16 1 p =0.16 2/16 1 p= 0.32
Residual tumor 6/57 ¥ (0, ¥) 12/57 2.1 (0.47, 9.5)
Baseline triple-negative status
non-TNBC 3/51 1 p =0.30 8/51 1 p= 0.26
TNBC 3/22 2.3 (0.46, 11.4) 6/22 1.8 (0.63, 5.2)
a Bold values are statistically significant.
HR= hazard ratio; N = lymph node; TNBC = triple-negative breast cancer; – indicates estimation not feasible because of low sample size in the
considered categories.
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HR 0.6; 95%CI 0.03, 8.8; Log rank test: p= 0.66).
Notably, however, of those patients without a
pCR, RFS rates were significantly lower in
patients with TNBC than those with non-TNBC
(3- and 5-year RFS estimates were 62% and 62%
for TNBC, and 89% and 79% for non-TNBC; HR
3.3; 95% CI 0.99, 10.8; Log rank test: p = 0.04)
[figure 2].
Safety
Chemotherapy was discontinued before all six
cycles were administered because of toxicity of at
least grade 3 severity in four patients and of grade
1 or 2 severity in a further four patients, but all
eight received surgery as per the study protocol
(after a median of four [range of two to five] cy-
cles of treatment).
Treatment-emergent adverse events are sum-
marized in table V, of which neutropenia was the
most frequently reported. Grade 4 febrile neu-
tropenia occurred in two patients. Two patients
experienced grade 2 peripheral neuropathy relat-
ed to docetaxel treatment. Interstitial pneumo-
pathy of grade 3 severity occurred in one patient
and was considered to be related to docetaxel
(table V), but did not lead to respiratory failure.
Only one patient developed a grade 3 cardiotox-
icity (acute heart failure), which was considered
to be related to epirubicin.
Treatment was delayed by 1 week for 46 pa-
tients (62%).
In addition, about one-fifth of patients had
more than one adverse event of at least grade 3
severity (n = 14) and one-half of patients experi-
enced at least one such adverse event (n = 39).
Four patients experienced serious treatment-
related adverse events; two cases of febrile neu-
tropenia, one case of allergic reaction, and one
case of pneumonia (the latter related to docetaxel
treatment). There were no treatment-related
deaths.
Discussion
Our patients had operable, non-inflammatory,
clinical stage II–III breast cancer, of whom most
had HER2-negative (HER2-) disease. After treat-
ment with two to three cycles each of alternating
gemcitabine plus docetaxel followed by vinor-
elbine plus epirubicin, about one-fifth of patients
had a complete response and survival rates were
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Fig. 2. Recurrence-free survival in patients with breast cancer
without a pathologic complete response after neoadjuvant treatment
with gemcitabine plus docetaxel alternating with vinorelbine plus
epirubicin according to triple-negative status. HR = hazard ratio;
TNBC = triple-negative breast cancer.
Table V. No. of treatment-emergent adverse events in the safety
population (n= 74)
Adverse event NCI CTC Grade
1 2 3 4
Hematologic toxicities
Anemia 7 6 0 0
Neutropenia 15 10 28 12
Febrile
neutropenia
0 0 0 2
Fever 4 1 0 0
Thrombopenia 7 5 0 0
Non-hematologic toxicities
Diarrhea 3 0 0 1
Skin eruption 10 6 0 0
Nausea/vomiting 13 6 0 1
Mucositis 11 4 0 0
Alopecia 3 6
Allergy 5 1 2 0
Neuropathy 3 2 0 0
Asthenia 6 7 0 0
Other 17 8 3a 0
a One patient had a cardiotoxicity (acute heart failure), one patient
had phlebitis, one had idiopathic interstitial pneumopathy.
NCI CTC=National Cancer Institute Common Toxicity Criteria, v.2.[22]
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The pCR rate falls within the range reported
in other neoadjuvant chemotherapy trials in pa-
tients with operable breast cancer (6–29%),[4]
is similar to that reported after the commonly
used neoadjuvant combination of docetaxel plus
doxorubicin plus cyclophosphamide in a similar
patient population (21%),[17] and is higher than
that reported for concomitantly administered
neoadjuvant combination regimens using a 3- or
4-weekly dosing schedule (12–15%).[3,25,26] How-
ever, caution should be applied when making such
comparisons because of differences in patient
populations and in definitions of pCR across
studies.
Recent studies assessing sequential and/or al-
ternating chemotherapy have generally been in
the adjuvant setting.[16,27] In one study, investiga-
tors concluded that sequential chemotherapy
allows dose intensity to be maintained,[16] and
our study results support this. Our use of a dose-
dense regimen is, in turn, supported by their results
with a combination of doxorubicin, cyclophos-
phamide, and paclitaxel given in a 2-weekly reg-
imen that did not adversely affect the risk of local
recurrence of disease and significantly (p < 0.05)
improved OS and disease-free survival compared
with a 3-weekly regimen.[16] No such therapeutic
advantage was shown in a neoadjuvant setting
comparing dose-dense epirubicin plus cyclophos-
phamide with standard fluorouracil plus epi-
rubicin plus cyclophosphamide in patients with
locally advanced or inflammatory breast cancer.[28]
However, our dose-dense regimen was associated
with good OS and RFS, and local disease re-
currence occurred only in 1.4% of patients.
In our exploratory analysis, baseline clinical
stage was prognostic of OS and RFS, baseline
tumor grade of OS, and baseline lymph node
status of RFS. We determined nodal response,
which was observed in 36% of our patients. This
good lymph node response may have con-
tributed, in part, to the good survival outcomes in
our study, because negative axillary nodes after
neoadjuvant therapy predict favorable long-term
outcomes.[23]
Approximately one-third of our patients had
TNBC, which is higher than expected since
TNBCs typically comprise 15% of breast cancer
cases.[15] Our enrollment was slightly skewed in
favor of TNBC because we aimed to exclude
patients with HER2+ disease, yet we did not se-
lect based on hormone receptor status in addition
to this (i.e. we did not preselect for TNBC). We
postulate that due to the aggressive nature of
TNBC, and that these tumors are often larger,[6-8]
patients with TNBC are more likely to be candi-
dates for neoadjuvant therapy. To our knowl-
edge, there is no direct evidence in the literature
to support this, but two studies in patients with
stage II–III breast cancer receiving neoadjuvant
therapy reinforce our hypothesis because they
too reported about one-third of patients with
TNBC.[10,13]
It has been suggested that patients with TNBC
are candidates for more aggressive chemothera-
py.[29] Our dose-dense alternating sequence of
anthracycline- and taxane-based combinations
showed significantly better activity in patients
with TNBC than in those with non-TNBC (pCR
40.9% vs 14.0%; p= 0.028). Our results are con-
cordant with several studies demonstrating a
better response to neoadjuvant therapy in TNBC
than non-TNBC.[10,11,13,14] The anti-tumor ac-
tivity of our regimen in patients with TNBC was
also associated with improved long-term prog-
nosis approaching that of patients without
TNBC; between-group differences in OS or RFS
were not significant. In contrast to our results,
other studies have found that despite a higher
pCR in patients with TNBC, the risk of death and
relapse was significantly higher in TNBC than
patients without TNBC,[10,11] or in TNBC (basal-
like tumor subtype) than in luminal tumor sub-
types.[13] Progression-free survival was 63% in
TNBC versus 76% in non-TNBC (HR 1.86; 95%
CI 1.39, 2.50) after neoadjuvant therapy in one
such study,[11] but importantly, this difference
was no longer apparent after more than 3 years of
follow-up (corresponding to our median follow-
up time). Our exploratory analyses revealed that
improved survival in patients with TNBC was
exclusively in those who had a pCR. Amongst
patients without a pCR, the prognosis of patients
with TNBCwas significantly (p= 0.04) poorer than
patients without TNBC (figure 2). These observa-
tions are concordant with previous reports;[11,13] for
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example, Carey et al.[13] found that patients with
basal-like tumors with residual disease have higher
relapse rates and poorer prognosis than those
without basal-like tumors who did not achieved
a pCR after anthracycline-based neoadjuvant
therapy.
Numerous study limitations must be consid-
ered when interpreting our results, including the
small patient population, relatively short follow-
up, lack of molecular/hormone receptor data for
all patients, and that the study was powered to
examine pCR, making all other analyses explor-
atory in nature. Our inclusion criteria were not
strictly adhered to, as nine patients were HER2+.
Despite these limitations, we were able to de-
monstrate that a dose-dense taxane-based regi-
men, with therapy delivered over a shorter total
period of time, allows for sequential administra-
tion of a dose-dense anthracycline-based regi-
men, which may help to limit resistance.[15]
Only one patient experienced a severe treat-
ment-related cardiotoxic adverse event. During
follow-up, there was no late cardiotoxicity, second-
ary acute myelogenous leukemia, or myelodys-
plastic syndrome; however, longer follow-up may
be required before such adverse events become ap-
parent. No patients experienced severe neuropathy
and there were only two serious or severe treat-
ment-related pulmonary adverse events (grade 3
interstitial pneumopathy and serious pneumonia).
As expected, neutropenia was the most frequently
reported toxicity overall, and the most common
severe adverse event despite filgrastim support.
However, no patients were hospitalized for neutro-
penia or febrile neutropenia. We conclude that
overall, themajority of adverse events weremanage-
able and, given that there were no treatment-related
deaths, this four-drug regimen was associated with
an acceptable tolerability profile.
Conclusion
A regimen of dose-dense combinations of gem-
citabine plus docetaxel and vinorelbine plus epi-
rubicin, given in an alternating sequence was
associated with favorable survival rates in patients
with TNBC, but only in those patients with a pCR.
Dose intensity was conserved with just three cycles
of each combination to produce a good pCR rate
and an acceptable tolerability profile. We recom-
mend that this regimen be further explored in a
prospective study in patients with TNBC.
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